Annals of Neurology · 2010 · 544 citations · 15 references
Life SciencesImmunologyPathologyAutoimmunityImmunopathologyNeuromuscular DisordersAutoantibodiesAutoantigensAutoimmune Disease PathogenesisAutoimmune Disease PathologyAutoimmune DiseasesMyasthenia GravisAchr Antibody-mediated DiseaseAnti-acetylcholine Receptor AntibodiesAnti-muscle-specific Kinase AntibodiesAntibodiesMuscle-specific Kinase AntibodiesMusk Antibody-mediated DiseaseNeuromuscular Junction Antibodies
Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction, where acetylcholine receptor (AChR), muscle-specific kinase (MuSK), and low-density lipoprotein (LDL) receptor-related protein 4 (Lrp4) are essential. About 80% and 0% to 10% of patients with generalized MG have autoantibodies to AChR and MuSK, respectively, but pathogenic factors are elusive in others. Here we show that a proportion of AChR antibody-negative patients have autoantibodies to Lrp4. These antibodies inhibit binding of Lrp4 to its ligand and predominantly belong to the immunoglobulin G1 (IgG1) subclass, a complement activator. These findings together indicate the involvement of Lrp4 antibodies in the pathogenesis of AChR antibody-negative MG.
15
Antibody to acetylcholine receptor in myasthenia gravis
Jon Lindstrom, Marjorie E. Seybold, Vanda A. Lennon et al. · Neurology · 1976 · 1.2K citations · Full text
Life Sciences, Immunology, Neurology +12
Lrp4 Is a Receptor for Agrin and Forms a Complex with MuSK
Natalie Kim, Amy L. Stiegler, Thomas O. Cameron et al. · Cell · 2008 · 673 citations · Full text